Volitinib (Savolitinib) is an ATP-competitive inhibitor that has been clinically evaluated in gastric cancer PDX models and showed high anti-tumor efficacy in bearing-amplified MET-selected individuals [117]. The gene discussed is MET; the disease is neoplasm.